Quan Meng-Jie, Lin Qiang
Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu 062552, Hebei Province, China.
World J Gastrointest Oncol. 2025 Jun 15;17(6):105085. doi: 10.4251/wjgo.v17.i6.105085.
There is no standard treatment for patients with locally advanced gastric cancer (LAGC). Neoadjuvant immunochemotherapy (NICT) is an emerging therapeutic strategy in LAGC. The prognosis of patients undergoing NICT plus radical surgery varies. Hypercoagulation is frequently identified in cancer patients. A retrospective study by Li confirmed that in LAGC patients undergoing radical resection post-NICT, elevated D-dimer and fibrinogen levels were associated with poor prognosis, and their combined assessment improved predictive accuracy. This retrospective study has some limitations, and further prospective research is required to validate hypercoagulation as a prognostic indicator and develop a more precise predictive model. Establishing such a model can facilitate personalized treatment strategies for patients with LAGC.
局部晚期胃癌（LAGC）患者尚无标准治疗方案。新辅助免疫化疗（NICT）是LAGC中一种新兴的治疗策略。接受NICT加根治性手术的患者预后各不相同。癌症患者中经常发现高凝状态。李的一项回顾性研究证实，在接受NICT后根治性切除的LAGC患者中，D-二聚体和纤维蛋白原水平升高与预后不良相关，联合评估可提高预测准确性。这项回顾性研究存在一些局限性，需要进一步的前瞻性研究来验证高凝状态作为预后指标，并开发更精确的预测模型。建立这样一个模型可以促进LAGC患者的个性化治疗策略。
